Haisco Pharmaceutical Group Co., Ltd. (SHE:002653)

SHE:002653 Revenue

Haisco Pharmaceutical Group had revenue of 1.53B CNY in the quarter ending June 30, 2026, with 38.13% growth. This brings the company's total for the last twelve months to 5.48B, up 35.86% year-over-year. In the year 2025, Haisco Pharmaceutical Group had annual revenue of 4.39B with 17.91% growth. That makes Haisco Pharmaceutical Group the 8,558th largest company in the world by revenue and 1,313th in China.

• Revenue (ttm): 5.48B
• Revenue Growth: +35.86%
• P/S Ratio: 11.94
• Revenue / Employee: 979.55K
• Employees: 5,597
• Market Cap: 66.59B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Parent Company 4.40B 49.7%
• Tibet Pharmaceuticals Merger 2.55B 28.8%
• Liaoning Hisun 548.14M 6.2%
• Tibet Haize 534.79M 6.0%
• Sichuan Hisun Corporation Merger 530.58M 6.0%
• Shenyang Hisun 287.23M 3.2%

Fiscal year ended Dec 31, 2025 See the full SHE:002653 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	4.39B	666.44M	17.91%
Dec 31, 2024	3.72B	366.28M	10.92%
Dec 31, 2023	3.36B	339.78M	11.27%
Jan 1, 2023	3.02B	241.98M	8.73%
Jan 1, 2022	2.77B	-556.28M	-16.71%

Data Source: S&P Global Market Intelligence Last updated: Aug 26, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 22, 2026

Data Sources Report a data error